Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL). To increase durable antitumor response, we previously designed tandem CART19/20 cells and shown longer progression-free survival. However, a proportion of CART19/20-treated patients will finally progress and require salvage therapies. In this study, we analyzed data from five patients with relapsed/refractory DLBCL who had disease progression or relapse following CART19/20 therapy and then treated with PD-1-blocking antibodies as salvage therapy. Two of five patients acquired complete remissions after anti-PD-1 therapy, including one patient remained ongoing remission for more than 21 months. One patient achieved a partial remission, and the other two had progressive diseases. No ≥ grade 3 treatment-related adverse events or cytokine release syndrome was observed. Immunohistochemistry of tumor specimens revealed higher PD-1/PD-L1 expression in responsive patients with anti-PD-1 therapy as compared to that in non-responders. After anti-PD-1 treatment, circulating T cells were activated in responders, and no significant expansion of CART19/20 cells was detected. Our data suggest that PD-1 blockade therapy can be active in patients with relapsed/refractory DLBCL after failure of CAR T cell therapy who had PD-L1 expression in tumor cells and high PD-1 level in tumor-infiltrated T cells.
Errataetall: |
ErratumIn: J Hematol Oncol. 2021 Sep 23;14(1):150. - PMID 34556168 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Journal of hematology & oncology - 14(2021), 1 vom: 05. Juli, Seite 106 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Chunmeng [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 01.11.2021 Date Revised 01.11.2021 published: Electronic ErratumIn: J Hematol Oncol. 2021 Sep 23;14(1):150. - PMID 34556168 Citation Status MEDLINE |
---|
doi: |
10.1186/s13045-021-01120-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM32772370X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM32772370X | ||
003 | DE-627 | ||
005 | 20231225201420.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13045-021-01120-3 |2 doi | |
028 | 5 | 2 | |a pubmed24n1092.xml |
035 | |a (DE-627)NLM32772370X | ||
035 | |a (NLM)34225766 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Chunmeng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.11.2021 | ||
500 | |a Date Revised 01.11.2021 | ||
500 | |a published: Electronic | ||
500 | |a ErratumIn: J Hematol Oncol. 2021 Sep 23;14(1):150. - PMID 34556168 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL). To increase durable antitumor response, we previously designed tandem CART19/20 cells and shown longer progression-free survival. However, a proportion of CART19/20-treated patients will finally progress and require salvage therapies. In this study, we analyzed data from five patients with relapsed/refractory DLBCL who had disease progression or relapse following CART19/20 therapy and then treated with PD-1-blocking antibodies as salvage therapy. Two of five patients acquired complete remissions after anti-PD-1 therapy, including one patient remained ongoing remission for more than 21 months. One patient achieved a partial remission, and the other two had progressive diseases. No ≥ grade 3 treatment-related adverse events or cytokine release syndrome was observed. Immunohistochemistry of tumor specimens revealed higher PD-1/PD-L1 expression in responsive patients with anti-PD-1 therapy as compared to that in non-responders. After anti-PD-1 treatment, circulating T cells were activated in responders, and no significant expansion of CART19/20 cells was detected. Our data suggest that PD-1 blockade therapy can be active in patients with relapsed/refractory DLBCL after failure of CAR T cell therapy who had PD-L1 expression in tumor cells and high PD-1 level in tumor-infiltrated T cells | ||
650 | 4 | |a Letter | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Anti-PD-1 | |
650 | 4 | |a CART | |
650 | 4 | |a DLBCL | |
650 | 4 | |a PD-1/PD-L1 | |
650 | 4 | |a Salvage therapy | |
650 | 7 | |a Antigens, CD19 |2 NLM | |
650 | 7 | |a Antigens, CD20 |2 NLM | |
650 | 7 | |a CTL019 chimeric antigen receptor |2 NLM | |
650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
700 | 1 | |a Shi, Fengxia |e verfasserin |4 aut | |
700 | 1 | |a Liu, Yang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yajing |e verfasserin |4 aut | |
700 | 1 | |a Dong, Liang |e verfasserin |4 aut | |
700 | 1 | |a Li, Xiang |e verfasserin |4 aut | |
700 | 1 | |a Tong, Chuan |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yao |e verfasserin |4 aut | |
700 | 1 | |a Su, Liping |e verfasserin |4 aut | |
700 | 1 | |a Nie, Jing |e verfasserin |4 aut | |
700 | 1 | |a Han, Weidong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of hematology & oncology |d 2008 |g 14(2021), 1 vom: 05. Juli, Seite 106 |w (DE-627)NLM180433709 |x 1756-8722 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2021 |g number:1 |g day:05 |g month:07 |g pages:106 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13045-021-01120-3 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2021 |e 1 |b 05 |c 07 |h 106 |